Evidence map›Paper›PMID 42196470›Full record

ReviewInternational journal of molecular sciences2026

The Role of Sigmar1 in Autophagy Regulation and Disease Therapy.

Huanqing Ge, Yusi Lin, Junda Li, Renwen Zhang, Cangcang Xu

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huanqing GeKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Pharmaceutical Sciences, Health Science Center, Hunan Normal University, Changsha 410013, China.
Yusi LinKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Pharmaceutical Sciences, Health Science Center, Hunan Normal University, Changsha 410013, China.
Junda LiKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Pharmaceutical Sciences, Health Science Center, Hunan Normal University, Changsha 410013, China.
Renwen ZhangKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Pharmaceutical Sciences, Health Science Center, Hunan Normal University, Changsha 410013, China.
Cangcang XuKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Pharmaceutical Sciences, Health Science Center, Hunan Normal University, Changsha 410013, China.ORCID 0000-0002-8086-6212

Funding

National College Student Innovation and Entrepreneurship Training Program 202412652001National Natural Science Foundation of China 82404692
6 · The paper itself

Abstract

Sigmar1 is a multifunctional molecular chaperone protein located on the Mitochondria-associated endoplasmic reticulum membranes (MAM). Recent studies have shown that Sigmar1 is not only a regulatory protein involved in cellular stress responses but also plays a significant role in the process of autophagy. It regulates the initiation and progression of autophagy by influencing multiple autophagy-related signaling pathways and interacting with key proteins such as LC3 and GABARAP. This regulation exhibits a dual nature. On one hand, it can induce protective autophagy, helping cells cope with stress such as oxidative stress and endoplasmic reticulum stress, thereby playing a protective role in the progression of diseases such as neurodegenerative disorders and cardiovascular diseases. On the other hand, in certain cancers, Sigmar1 may also promote tumor cell survival through autophagy regulation, thereby exacerbating disease progression. Consequently, developing agonists and antagonists targeting Sigmar1 has become a highly promising therapeutic strategy. This review provides a systematic overview of recent advances in the biological characterization of Sigmar1 and its molecular mechanisms in regulating autophagy. It summarizes the multifaceted roles of Sigmar1 in various diseases and discusses current research progress and the application prospects of Sigmar1 agonists and antagonists, aiming to establish a theoretical foundation for the development of novel Sigmar1-based therapeutic strategies for human diseases.

Indexed as

AutophagyNeoplasmsNeurodegenerative DiseasesReceptors, sigmaAnimalsCardiovascular DiseasesEndoplasmic Reticulum StressHumansOxidative StressSigma-1 ReceptorSignal TransductionReceptors, sigmaSigma-1 Receptoragonists and antagonistsautophagydisease therapyregulatory mechanismSigmar1

Identifiers

PMID42196470
PMCPMC13207866

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.